Nebenwirkungen · Privigen
Privigen 100 mg/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-118953 · Präparat HOS-094881
In Privigen clinical studies with paediatric patients, the frequency, nature and severity of adverse reactions did not differ between children and adults. In post marketing reports it is observed that the proportion of haemolysis cases to all case reports occurring in children is slightly higher than in adults. Please refer to section 4.4 for details on risk factors and monitoring recommendations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-24T02:00:00Z · SHA-256 208a630b72cbe4bf06dce638906eae5709b3d2c4ac99de003201ffa973213cd0 · Passage 68e7619f1031a503fb4d84f7c0cb88f945b4e823cb0b2291cf7612315f2d0a5f · Zeichen 9170–9570 im Abschnitt